Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BlueStone Capital Reiterates STRONG BUY Rating on Premier Laser Systems.


NEW YORK--(BW HealthWire)--May 9, 1997--Senior Analyst, Scott Baily at BlueStone bluestone, common name for the blue, crystalline heptahydrate of cupric sulfate called chalcanthite, a minor ore of copper. It also refers to a fine-grained, light to dark colored blue-gray sandstone.  Capital reiterates his investment rating on Premier Laser Systems, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: PLSIA) of a STRONG BUY recommendation.

-- On May 7, 1997, PLSIA announced that the company received FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 approval of its Centauri Erbium erbium (ûr`bēəm) [from Ytterby, a town in Sweden], metallic chemical element; symbol Er; at. no. 68; at. wt. 167.26; m.p. 1,529°C;; b.p. 2,863°C;; sp. gr. 9.05 at 25°C;; valence +3. : YAG laser YAG laser Yttrium-aluminum-garnet laser, Nd:YAG–neodymium:yttrium-aluminum-garnet–laser. See Laser.  for hard-tissue procedures. The FDA clearance to market its Centauri laser is the first-ever granted in the U.S., and effectively gives PLSIA, in our opinion, a 1 1/2 to 3 year lead over the competition.

-- Following PLSIA's FDA approval of the Centauri this week, we are reiterating our STRONG BUY recommendation for long-term investors. In our view, the long-term outlook for the company continues to get better. However, given the nearly doubling of PLSIA's stock price -- up 95% -- since our most recent recommendation at $5 5/8, we would not be surprised to see some short-term profit taking.

-- With institutional investors currently holding less than 1% of PLSIA's common stock outstanding, we believe considerable institutional demand is likely in the months ahead. Additionally, since we are the only research coverage on Wall Street, as more analysts begin to follow the company, we would anticipate that the added sponsorship would also favorably impact the stock.

BlueStone Capital Partners, L.P. is a full service investment banking and brokerage firm that delivers financial services The examples and perspective in this article or section may not represent a worldwide view of the subject.
Please [ improve this article] or discuss the issue on the talk page.
 to emerging growth and medium size companies worldwide. BlueStone Capital assists clients in maximizing their growth by providing sophisticated investment strategies that are designed to achieve clients' strategic, operating and financial goals.

CONTACT: BlueStone Capital Partners, L.P.

Scott Baily, 212/850-0558
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 9, 1997
Words:263
Previous Article:CellNet testifies on deregulation to Congressional Subcommittee on Energy and Power.
Next Article:Advantage Bancorp Inc. to buy back up to 5 percent of stock over 6 months.
Topics:



Related Articles
BlueStone Capital initiates Coverage With a Buy recommendation on Premier Laser Systems, Inc.
Blue Stone Capital Reiterates STRONG BUY rating on Premier Laser Systems.
BlueStone Capital Partners, L.P., Initiates Coverage On Coherent, Inc. With a Long - Term Buy Rating.
BlueStone Capital Partners Announces Investment Opinion on Candela Corporation.
BlueStone Capital Partners Announces Investment Opinion on Candela Corporation.
BlueStone Capital Partners Announces Investment Opinion on Coherent, Inc.
BlueStone Capital Partners Announces Investment Opinion on Candela Corporation.
BlueStone Capital Partners Announces Investment Opinion on Biolase Technology, Inc.
BlueStone Capital Announces Investment Opinion on Coherent, Inc.
Bluestone closes $280m in deals during 1st qtr.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles